Prognostic value of CA 125 in advanced ovarian cancer.
作者： Ole Mogensen
DOI: 10.1016/0090-8258(92)90043-I
关键词:
摘要: Abstract CA 125 was measured during early chemotherapy in 121 patients with FIGO stage III or IV ovarian cancer to investigate if the antigen could be used as a prognostic parameter. determined before start of and 1 month after first, second, third course. The level held no information. significant parameter all three courses but its correlation survival improved number courses. Patients high marker levels (>100 U/ml) course had median 7 months. This should compared 50% 5-year who 10 U/ml less 22 months among intermediate levels. Cox regression analysis covariation between survival, 125, five variables (age, stage, histopathology, tumor grade, bulk residual tumor) showed that value most As consequence this study, may discontinued replaced by palliative therapy other curative regimens are not available.
gynecologiconcology-online.net
elsevier.com
sci-hub.se 参考文章(10)
ATE G. J. ZEE, JITZE M. DUK, JAN G. AALDERS, AB H. BOONTJE, KLASKE A. TEN HOOR, HENK W. A. BRUIJN, The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. British Journal of Obstetrics and Gynaecology. ,vol. 97, pp. 934- 938 ,(1990) , 10.1111/J.1471-0528.1990.TB02450.X
Donald E. Pittaway, Correlation of an enzyme immunoassay with the radioimmunoassay for CA-125 American Journal of Obstetrics and Gynecology. ,vol. 158, pp. 62- 64 ,(1988) , 10.1016/0002-9378(88)90777-6
D.J. CRUICKSHANK, W. T. FULLERTON, A. KLOPPER, The clinical significance of pre-operative serum CA 125 in ovarian cancer British Journal of Obstetrics and Gynaecology. ,vol. 94, pp. 692- 695 ,(1987) , 10.1111/J.1471-0528.1987.TB03177.X
A. Rosen, P. Sevelda, M. Klein, J. Spona, A. Beck, A CA125 score as a prognostic index in patients with ovarian cancer. Archives of Gynecology and Obstetrics. ,vol. 247, pp. 125- 129 ,(1990) , 10.1007/BF02390860
K. Bertelsen, A. Jakobsen, J.E. Andersen, S. Ahrons, P.Hjortkjær Pedersen, H. Kiær, E. Arffmann, P. Bichel, E. Boestofte, I.Strøyer Christophersen, E. Gregersen, M.Kern Hansen, B. Hølund, M. Jacobsen, H.Kaalund Jensen, F.Løve Jepsen, G. Larsen, E.Sandberg Nielsen, M. Nyland, J. Olsen, J. Panduro, F. Rank, A. Sell, H. Søgaard, A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma Gynecologic Oncology. ,vol. 28, pp. 161- 169 ,(1987) , 10.1016/0090-8258(87)90210-1
Ole Mogensen, Bent Mogensen, Anders Jakobsen, Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer Gynecologic Oncology. ,vol. 37, pp. 44- 46 ,(1990) , 10.1016/0090-8258(90)90305-5
Ole Mogensen, Bent Mogensen, Anders Jakobsen, Alpha1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125 Cancer. ,vol. 64, pp. 1867- 1871 ,(1989) , 10.1002/1097-0142(19891101)64:9<1867::AID-CNCR2820640919>3.0.CO;2-Y
Charles W.E. Redman, George R. Blackledge, Krystyna Kelly, Judith Powell, Edward J. Buxton, David M. Luesley, Early serum CA125 response and outcome in epithelial ovarian cancer. European Journal of Cancer and Clinical Oncology. ,vol. 26, pp. 593- 596 ,(1990) , 10.1016/0277-5379(90)90085-8
MEL Van der Burg, FB Lammes, WLJ Van Putten, G Stoter, None, Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecologic Oncology. ,vol. 30, pp. 307- 312 ,(1988) , 10.1016/0090-8258(88)90244-2
Robert C. Bast, Thomas L. Klug, Elena St. John, Eric Jenison, Jonathan M. Niloff, Herbert Lazarus, Ross S. Berkowitz, Thomas Leavitt, C. Thomas Griffiths, Leroy Parker, Vincent R. Zurawski, Robert C. Knapp, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. The New England Journal of Medicine. ,vol. 309, pp. 883- 887 ,(1983) , 10.1056/NEJM198310133091503